Sorafenib for patients with differentiated thyroid cancer – Authors' reply

Publisher Website

1 January 2015

journal article
Published by Elsevier BV in The Lancet

Vol. 385 (9964), 228-229
https://doi.org/10.1016/s0140-6736(15)60056-3

Abstract

No abstract available

This publication has 1 reference indexed in Scilit:

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
The Lancet, 2014

Cited by 4 articles